Vivos Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vivos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Vivos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$2.83M, a 33.6% increase year-over-year.
  • Vivos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$11.1M, a 18% increase year-over-year.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$11.1M, a 18% increase from 2023.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$13.6M, a 43% increase from 2022.
  • Vivos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$23.8M, a 17.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$11.1M +$2.45M +18% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$13.6M +$10.3M +43% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$23.8M -$3.56M -17.5% Jan 1, 2022 Dec 31, 2022 10-K/A 2024-07-30
2021 -$20.3M -$8.23M -68.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$12.1M -$1.3M -12.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$10.8M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.